Truist Financial Cuts Humana (NYSE:HUM) Price Target to $305.00

Humana (NYSE:HUM) had its target price decreased by investment analysts at Truist Financial from $325.00 to $305.00 in a report issued on Monday,Benzinga reports. The firm presently has a “hold” rating on the insurance provider’s stock. Truist Financial’s target price would indicate a potential upside of 21.65% from the company’s previous close.

A number of other research firms have also issued reports on HUM. Morgan Stanley lowered their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Oppenheimer upped their price objective on shares of Humana from $300.00 to $310.00 and gave the company an “outperform” rating in a research note on Thursday, May 1st. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price target on shares of Humana in a research note on Thursday, May 1st. StockNews.com raised Humana from a “hold” rating to a “buy” rating in a research report on Friday. Finally, JPMorgan Chase & Co. cut their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Seventeen analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $286.81.

Humana Stock Performance

HUM stock traded up $1.19 during midday trading on Monday, reaching $250.72. The company had a trading volume of 774,341 shares, compared to its average volume of 1,742,005. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $30.26 billion, a PE ratio of 25.19, a P/E/G ratio of 2.05 and a beta of 0.49. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The stock has a 50 day moving average price of $265.21 and a 200 day moving average price of $270.47.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a net margin of 1.02% and a return on equity of 11.70%. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. During the same quarter last year, the business earned $7.23 earnings per share. Humana’s revenue was up 8.4% compared to the same quarter last year. Analysts anticipate that Humana will post 16.47 earnings per share for the current year.

Institutional Investors Weigh In On Humana

Institutional investors and hedge funds have recently modified their holdings of the company. FPC Investment Advisory Inc. purchased a new position in shares of Humana during the fourth quarter worth about $27,000. Centricity Wealth Management LLC bought a new position in shares of Humana in the fourth quarter worth approximately $30,000. Cary Street Partners Investment Advisory LLC increased its holdings in Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after purchasing an additional 46 shares during the period. LFA Lugano Financial Advisors SA boosted its holdings in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares in the last quarter. Finally, OFI Invest Asset Management bought a new position in Humana in the fourth quarter worth about $33,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.